Wellmark Blue Cross & Blue Shield has decided to rescind a controversial proposal whereby hospitals in South Dakota would have been asked to report modifiers on claims to denote the use of drugs acquired under the 340B program by April 1. Â
Wellmark made the decision to reevaluate the proposed policy after receiving a joint-letter from the South Dakota Association of Healthcare Organizations (SDAHO) and Iowa Hospital Association (IHA), which outlined significant concerns from their members.